TEL
AVIV, Israel, ZURICH and
NEW YORK, Sept. 6,
2023 /PRNewswire/ -- SHL Telemedicine
Ltd. (SIX Swiss Exchange: SHLTN) (NASDAQ: SHLT) ("SHL" or
the "Company"), a leading provider and developer of advanced
personal telemedicine solutions, today announced that it will issue
its Half-year 2023 results before market opens on Thursday, September 21, 2023.
The conference call for investors, journalists, and analysts to
discuss the half-year results 2023 will be hosted by Erez
Nachtomy, CEO, and Amir Hai,
CFO, and has been scheduled for:
Date: Thursday, 21 September
2023
Time: 4 pm CET / 10 am ET / 5 pm
Israel Time
The conference call can be accessed live via the dial-in
numbers:
From Europe
+41 (0)58 310 50 00
From the UK
+44 (0) 207 107 06 13
From the USA
+1 (1)
631 570 56 13
From Israel
+972 3763 1173
Toll free:
1 80 921 44 27
Local:
+972 3763 1173
Other international numbers are available here.
After the presentation, there will be an open Q&A. The
conference call is scheduled to last 40-60 minutes and will be held
in English.
The press release and the presentation slides will be made
available at the company website www.shl-telemedicine.com at
7.00 am CET on 21 September 2023.
About SHL Telemedicine
SHL Telemedicine is engaged in developing and marketing personal
telemedicine systems and the provision of medical call center
services, with a focus on cardiovascular and related diseases, to
end users and to the healthcare community. SHL Telemedicine offers
its services and personal telemedicine devices to subscribers
utilizing telephonic and Internet communication technology. SHL is
listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885,
Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT,
ISIN: US78423T2006, CUSIP: 78423T200). For more information, please
visit our website at www.shl-telemedicine.com.
Logo: https://mma.prnewswire.com/media/1850421/SHL_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/shl-telemedicine-half-year-results-2023-and-conference-call-scheduled-for-september-21-2023-301919050.html
SOURCE SHL Telemedicine Ltd.